What's in EuBiologics Co.,Ltd's pipeline?

EuBiologics Co.,Ltd has 12 drugs in our index: 0 marketed, 0 filed, 5 in Phase 3, 1 in Phase 2, 6 in Phase 1.

Which companies overlap with EuBiologics Co.,Ltd's portfolio?

Top competitors by shared drug class: London School of Hygiene and Tropical Medicine, University of Oxford, Aeras, Amir Moradi MD, MBA, Beth Israel Deaconess Medical Center.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/eubiologics-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

EuBiologics Co.,Ltd — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

EuBiologics Co.,Ltd pipeline: 0 marketed, 0 filed, 5 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 5 Phase 3 1 Phase 2 6 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Euvichol	Euvichol	phase 3			Other
EuCorVac-19	EuCorVac-19	phase 3	Recombinant protein subunit vaccine	SARS-CoV-2 spike protein (S protein)	Immunology / Infectious Disease
ATGC-100 100U	ATGC-100 100U	phase 3	Anticoagulant (antithrombin-based)	Thrombin and coagulation factors (Factor Xa, IIa, and others)	Cardiovascular / Hematology
ChAdOx1 nCoV-19	ChAdOx1 nCoV-19	phase 3	Viral vector vaccine	SARS-CoV-2 spike protein	Immunology / Infectious Disease
Botox 100U	Botox 100U	phase 3	Botulinum toxin	SNARE complex (synaptosomal-associated protein)	Neurology, Dermatology, Aesthetics

Therapeutic area mix

Immunology / Infectious Disease · 2
Cardiovascular / Hematology · 1
Neurology, Dermatology, Aesthetics · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

London School of Hygiene and Tropical Medicine · 2 shared drug classes
University of Oxford · 2 shared drug classes
Aeras · 1 shared drug class
Amir Moradi MD, MBA · 1 shared drug class
Beth Israel Deaconess Medical Center · 1 shared drug class
Bharat Biotech International Limited · 1 shared drug class
CanSino Biologics Inc. · 1 shared drug class
Allergan · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for EuBiologics Co.,Ltd:

Cite this brief

Drug Landscape (2026). EuBiologics Co.,Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/eubiologics-co-ltd. Accessed 2026-06-10.